Biosimilars

Biosimilars are a rapidly growing treatment option for physicians treating advanced diseases, with more than 20 unique biosimilars expected to enter the U.S. healthcare market over the next decade. Learn more about these safe and effective treatment options.

VIDEO
Uncovering the Path to Successful Biosimilar Adoption for Your Specialty Practice
If your specialty practice is preparing to adopt biosimilars, 威尼斯wns8885556-apple app store排行榜-威尼斯wns8885556有限公司-威尼斯wns8885556菠菜种植澳门科技有限公司 can help. We clear the path by creating a roadmap for success. Our advisors and resources can help you navigate every step of the biosimilar journey, from patient education to developing training programs. 威尼斯wns8885556-apple app store排行榜-威尼斯wns8885556有限公司-威尼斯wns8885556菠菜种植澳门科技有限公司 also supports specialty practices like yours with communicating the facts clearly, implementing efficient workflows and driving operational excellence so you can focus on what matters most - caring for your patients.

Read below for biosimilar resources at every stage: biosimilar beginners, considerations when using biosimilars, and best practices post-adoption.

New to biosimilars?

Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from existing, FDA-approved reference biologics.
While biosimilars are similar to their reference biological product, they are not generic equivalents.
Biosimilars go through a rigorous FDA review process including analytical, animal and clinical studies.

Biosimilars go through an extensive FDA approval process and offer safe, effective therapeutic options for serious diseases

As more biosimilars become available in the U.S., providers, payers and patients all stand to benefit from further incorporating these safe and effective therapies throughout our healthcare ecosystem.

Rising healthcare costs, increasing drug production demands and reimbursement pressures are all putting a serious strain on our nation’s healthcare delivery system. By adopting biosimilars routinely into patient treatment decisions, we can improve overall access to critical, life-saving drugs all while reducing the costs of these expensive therapies through increased competition.

Learn more about the 威尼斯wns8885556-apple app store排行榜-威尼斯wns8885556有限公司-威尼斯wns8885556菠菜种植澳门科技有限公司 services available to support biosimilar and other practice needs by visiting our Solutions for Specialty Practices page.

Considering adopting biosimilars in your treatment regimens?

Biosimilars Currently Available through 威尼斯wns8885556-apple app store排行榜-威尼斯wns8885556有限公司-威尼斯wns8885556菠菜种植澳门科技有限公司 Include:
生物仿制药	Biologic Reference Drug	HCPCS Code	Patient Support Services	Full Prescribing Information
Alymsys (bevacizumab-maly)	Avastin	Q5126	Amneal PATHways	FDA Drug Info (PDF, 588 KB)
Mvasi (bevacizumab-awwb)	Avastin	Q5107	Amgen Assist 360	FDA Drug Info (PDF, 627 KB)
Vegzelma (bevacizumab-adcd)	Avastin	Q5129	Celltrion Connect	FDA Drug Info (PDF, 653 KB)
Zirabev (bevacizumab-bvzr)	Avastin	Q5118	Pfizer Oncology Together	FDA Drug Info (PDF, 1 MB)
Retacrit (epoetin alfa-epbx)	Epogen/Procrit	Q5105 (ESRD use) Q5106 (non-ESRD use)	Pfizer enCompassProgram	FDA Drug Info (PDF, 614 KB)
Herzuma (trastuzumab-pkrb)	Herceptin	Q5113	Teva Core Program	FDA Drug Info (PDF, 551 KB)
Kanjinti (trastuzumab-anns)	Herceptin	Q5117	Amgen Assist 360	FDA Drug Info (PDF, 834 KB)
Ogivri (trastuzumab-dkst)	Herceptin	Q5114	Ogivri Patient Assistance	FDA Drug Info
Ontruzant (trastuzumab-dttb)	Herceptin	Q5112	Merck Access Program	FDA Drug Info
Trazimera (trastuzumab-qyyp)	Herceptin	Q5116	Pfizer Oncology Together	FDA Drug Info (PDF, 706 KB)
Amjevita (adalimumab-atto)	Humira		Amjevita Support	FDA Drug Info
Byooviz (ranibizumab-nuna)	Lucentis	Q5124	Byooviz Patient Support Services	FDA Drug Info (PDF, 685 KB)
Cimerli (ranibizumab-eqrn)	Lucentis	Q5128	Cimerli Solutions	FDA Drug Info (PDF, 1.41 MB)
Fulphila (pegfilgrastim-jmdb)	Neulasta	Q5108	Mylan Advocate Portal	FDA Drug Info (PDF, 921 KB)
Fylnetra (pegfilgrastim-pbbk)	Neulasta	Q5130	Amneal PATHways	FDA Drug Info (PDF, 1.25 MB)
Nyvepria (pegfilgrastim-apgf)	Neulasta	Q5122	Pfizer Oncology Together	FDA Drug Info (PDF, 1 MB)
Stimufend (pegfilgrastim-fpgk)	Neulasta	Q5127	KabiCare	FDA Drug Info (PDF, 546 KB)
Udenyca (pegfilgrastim-cbqv)	Neulasta	Q5111	Coherus COMPLETE \| Support	FDA Drug Info (PDF, 1 MB)
Ziextenzo (pegfilgrastim-bmez)	Neulasta	Q5120	Sandoz One Source	FDA Drug Info
Nivestym (filgrastim-aafi)	Neupogen	Q5110	Pfizer enCompass	FDA Drug Info (PDF, 921 KB)
Releuko (filgrastim-ayow)	Neupogen	Q5125	Amneal PATHways	FDA Drug Info (PDF, 4 MB)
Zarxio (filgrastim-sndz)	Neupogen	Q5101	Sandoz OneSource	FDA Drug Info
Avsola (infliximab-axxq)	Remicade	Q5121	Amgen Assist	FDA Drug Info
Inflectra (infliximab-dyyb)	Remicade	Q5103	Pfizer enCompass	FDA Drug Info (PDF, 1 MB)
Renflexis (infliximab-abda)	Remicade	Q5104	Merck Access Program	FDA Drug Info (PDF, 537 KB)
Riabni (rituximab-arrx)	Rituxan	Q5123	Amgen Assist 360	FDA Drug Info (PDF, 468 KB)
Ruxience (rituximab-pvvr)	Rituxan	Q5119	Pfizer Oncology Together	FDA Drug Info (PDF, 811 KB)
Truxima (rituximab-abbs)	Rituxan	Q5115	Teva Core Program	FDA Drug Info (PDF, 402 KB)

Specialty DistributionSpecialty drugs for physician practices.

Specialty Customer LoginPhysician practice login.

Pharmacy DistributionFor pharmacies, health systems & hospitals.

Four Reasons to Consider Adopting Biosimilars for Your Treatment Regimens
扩大复杂疾病的治疗方案
Substantial Cost Savings on Expensive Therapies
FDA-Approved, Safe and Effective Treatments
Support from FDA and Other Leading Medical Advisory Organizations
Biosimilar 101 Resources
Biosimilar Master Class
Dr. Robert Rifkin and our team of expert clinical specialists and business advisors help you understand biosimilars from the U.S. Food and Drug Administration (FDA) perspective. While similar to biologic reference products, biosimilars have unique operational, clinical, and financial decision points critical to successfully implementing these therapies in your practice.
Learn More
A Guide to Navigating Biosimilars
From 2017 to 2020, 威尼斯wns8885556-apple app store排行榜-威尼斯wns8885556有限公司-威尼斯wns8885556菠菜种植澳门科技有限公司 helped specialty providers save more than $386 million dollars through biosimilar adoption. As the biosimilar landscape continues to evolve, we can expect to see more biosimilar treatment options for more conditions. 威尼斯wns8885556-apple app store排行榜-威尼斯wns8885556有限公司-威尼斯wns8885556菠菜种植澳门科技有限公司 is here to help you navigate the landscape, identify economic opportunities for your practice and provide resources to physicians who are evaluating biosimilars for their patients.
Download Guide
ADDITIONAL READING
Biosimilar Perspectives from 威尼斯wns8885556-apple app store排行榜-威尼斯wns8885556有限公司-威尼斯wns8885556菠菜种植澳门科技有限公司 Experts
Navigating Biosimilar Reimbursement: Key Challenges and Steps to Success
威尼斯wns8885556-apple app store排行榜-威尼斯wns8885556有限公司-威尼斯wns8885556菠菜种植澳门科技有限公司’s experts address the most important clinical, operational, and economical obstacles to overcome on the path to reimbursement.
Three Biosimilar Barriers in Community Clinic
An in depth look at the primary concerns of physicians when implementing biosimilars in their oncology and rheumatology practices.
From Clinical Use to Reimbursement
Dr. Robert Rifkin, medical director of biosimilars for 威尼斯wns8885556-apple app store排行榜-威尼斯wns8885556有限公司-威尼斯wns8885556菠菜种植澳门科技有限公司, gives an update on biosimilar education and reimbursement.
Perfect Storm for Biosimilar Marketing
Dr. Robert Rifkin discusses the "perfect storm" for biosimilar marketing in a recent OncLive article.
Biosimilars: A Recent Review of Clinical Outcomes
A review of 14,000 individuals transitioned from a reference biologic medication to a biosimilar examines patient safety and treatment efficacy.
Overcoming Physician Barriers to Biosimilar Adoption in Clinics (PDF, 228 KB)
Omar Hafez shares how biopharmaceutical companies can learn how to overcome the clinical, operational, and economic barriers to biosimilar adoption.
VIEWPOINT
Biosimilar Endorsements From Major Medical Advisory Organizations
Read about the benefits of biosimilar growth from major Oncology and Rheumatology advisory bodies.
Rheumatology | Oncology (PDF, 648 KB)
EDUCATION
CMS Medicare Guidance on Biosimilar Reimbursement
Stay up to date on new Medicare HCPCS codes and reimbursement guidance on biosimilars.
FDA Biosimilar Resources for Your Practice
Visit the FDA biosimilar website for provider and patient-facing biosimilar resources. Topics include the latest FDA approvals, biosimilar 101 education, regulatory review and approval, interchangeability guidance and more.
Related 威尼斯wns8885556-apple app store排行榜-威尼斯wns8885556有限公司-威尼斯wns8885556菠菜种植澳门科技有限公司 Products and Services

Oncology Practice Solutions Discover how we make your oncology practice more manageable.
Visit Page